Lawrence Schwartz
Overview
Explore the profile of Lawrence Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
5123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao B, Obuchowski N, Yang H, Chou Y, Ma H, Guo P, et al.
Radiol Adv
. 2025 Jan;
2(1):umaf001.
PMID: 39834611
Purpose: To assess agreement between CT volumetry change classifications derived from Quantitative Imaging Biomarker Alliance Profile cut-points (ie, QIBA CTvol classifications) and the Response Evaluation Criteria in Solid Tumors (RECIST)...
2.
McKelvey B, Garrett-Mayer E, Rivera D, Alabaster A, Andrews H, Bond E, et al.
JCO Clin Cancer Inform
. 2024 Aug;
8:e2400091.
PMID: 39146509
Purpose: Real-world data (RWD) holds promise for ascribing a real-world (rw) outcome to a drug intervention; however, ascertaining rw-response to treatment from RWD can be challenging. Friends of Cancer Research...
3.
Albertz M, Ing R, Schwartz L, Navaratnam M
Paediatr Anaesth
. 2024 Aug;
34(11):1119-1129.
PMID: 39092610
Patients with congenital heart disease are living longer due to improved medical and surgical care. Congenital heart disease encompasses a wide spectrum of defects with varying pathophysiology and unique anesthetic...
4.
Nakajima E, Simpson A, Bogaerts J, de Vries E, Do R, Garalda E, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300687.
PMID: 38635935
Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working...
5.
Gotlib J, Castells M, Elberink H, Siebenhaar F, Hartmann K, Broesby-Olsen S, et al.
NEJM Evid
. 2024 Feb;
2(6):EVIDoa2200339.
PMID: 38320129
BACKGROUND: Indolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. We assessed the efficacy and safety of avapritinib versus placebo, both with best supportive...
6.
Morris M, Heller G, Hillman D, Bobek O, Ryan C, Antonarakis E, et al.
J Clin Oncol
. 2023 Mar;
41(18):3352-3362.
PMID: 36996380
Purpose: Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought...
7.
Shankar L, Schoder H, Sharon E, Wolchok J, Knopp M, Wahl R, et al.
Lancet Oncol
. 2023 Mar;
24(3):e133-e143.
PMID: 36858729
As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy...
8.
Desperito E, Schwartz L, Capaccione K, Collins B, Jamabawalikar S, Peng B, et al.
Life (Basel)
. 2022 Nov;
12(11).
PMID: 36362854
Background: We report the results of our retrospective analysis of the ability of standard chest CT scans to correctly diagnose cancer in the breast. Methods: Four hundred and fifty-three consecutive...
9.
Schwartz L, Gundersen K
J Physiol
. 2022 Apr;
600(9):2087-2088.
PMID: 35388912
No abstract available.
10.
Olsen E, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, et al.
Blood
. 2021 Nov;
140(5):419-437.
PMID: 34758074
The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published...